{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01998971\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["daratumumab","carfilzomib","dexamethasone"],["daratumumab","pomalidomide","dexamethasone"],["daratumumab","carfilzomib","lenalidomide","dexamethasone"]],"indication":"multiple myeloma","name":"EQUULEUS","nct_id":"NCT01998971","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=equuleus-nct01998971. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Daratumumab will be administered with Velcade-dexamethasone (VD).","label":"Daratumumab + VD","type":"EXPERIMENTAL"},{"description":"Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).","label":"Daratumumab + VMP","type":"EXPERIMENTAL"},{"description":"Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).","label":"Daratumumab + VTD","type":"EXPERIMENTAL"},{"description":"Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).","label":"Daratumumab + Pom-dex","type":"EXPERIMENTAL"},{"description":"Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.","label":"Daratumumab + CFZ-dex","type":"EXPERIMENTAL"},{"description":"Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.","label":"Daratumumab + KRd","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-01-11","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":240,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Velcade","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Melphalan","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Thalidomide","otherNames":[],"type":"DRUG"},{"name":"Diphenhydramine","otherNames":[],"type":"DRUG"},{"name":"Acetaminophen","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"},{"name":"Montelukast","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2019-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)","timeFrame":"Up to 30 days after the last dose of study medication"},{"measure":"Number of participants affected by dose-limiting toxicities","timeFrame":"Up to 30 days after the last dose of study medication"}],"references":[{"citation":"Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosinol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33. doi: 10.1038/s41408-023-00805-x. No abstract available.","pmid":"36882409","type":"DERIVED"},{"citation":"He J, Berringer H, Heeg B, Ruan H, Kampfenkel T, Dwarakanathan HR, Johnston S, Mendes J, Lam A, Bathija S, Mackay EK. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. Adv Ther. 2022 Sep;39(9):4230-4249. doi: 10.1007/s12325-022-02226-x. Epub 2022 Jul 22.","pmid":"35876974","type":"DERIVED"},{"citation":"Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 Feb;62(2):358-367. doi: 10.1080/10428194.2020.1832672. Epub 2020 Oct 28.","pmid":"33112184","type":"DERIVED"},{"citation":"Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Blade J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 Apr;37(4):1464-1478. doi: 10.1007/s12325-020-01247-8. Epub 2020 Feb 20.","pmid":"32078124","type":"DERIVED"},{"citation":"Chari A, Martinez-Lopez J, Mateos MV, Blade J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.","pmid":"31113777","type":"DERIVED"},{"citation":"Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.","pmid":"28637662","type":"DERIVED"}],"start_date":{"date":"2014-02-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT01998971"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/equuleus-nct01998971"}